Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 9,813 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Advanced Malignancy Clear all

Conditions: Thyroid Cancer
Interventions: ZD6474 (Vandetanib); Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2024
U.S. locations: 32
States / cities: Little Rock, Arkansas • San Francisco, California • Aurora, Colorado + 13 more

Conditions: Advanced Solid Tumors
Interventions: MLN4924, Fluconazole, Itraconazole, Docetaxel, Carboplatin, Paclitaxel; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 4
States / cities: Atlanta, Georgia • St Louis, Missouri • Nashville, Tennessee + 1 more

Conditions: Breast Cancer
Interventions: Tobemstomig, Pembrolizumab, Nab-Paclitaxel; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: Los Alamitos, California • New York, New York • Charlotte, North Carolina + 1 more

Conditions: Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Carcinoma, Locally Advanced Pancreatic Cancer
Interventions: Avutometinib (VS-6766) + Defactinib (VS-6063); Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Cutaneous Melanoma, Pleural Mesothelioma, HER2 Negative Breast Neoplasms, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: SGN-CD228A; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 7 more

Conditions: Solid Tumor
Interventions: BS006 Injection; Drug
Lead sponsor: Binhui Biopharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Orlando, Florida • Detroit, Michigan

Conditions: Oropharyngeal Carcinoma
Interventions: 18F-FMISO PET/CT Scan, Chemoradiation, Questionnaires; Diagnostic Test · Combination Product · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: Cytarabine, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Questionnaire Administration, WEE1 Inhibitor AZD1775; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: gemcitabine hydrochloride, oxaliplatin; Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 3
States / cities: Duarte, California • Los Angeles, California • Sacramento, California

Conditions: Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic
Interventions: ABC294640, Hydroxychloroquine Sulfate 200 MG; Drug
Lead sponsor: RedHill Biopharma Limited; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Phoenix, Arizona • Atlanta, Georgia • Rochester, Minnesota + 2 more

Conditions: Neoplasm, Desmoid Tumor
Interventions: PF-03084014; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 16 Years to 101 Years
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions: bryostatin 1, cisplatin, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Duarte, California

Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Interventions: capecitabine, gemcitabine hydrochloride; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
Interventions: rezatapopt, pembrolizumab; Drug
Lead sponsor: PMV Pharmaceuticals, Inc; Industry
Eligibility: 12 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 32
States / cities: Irvine, California • La Jolla, California • Los Angeles, California + 26 more

Conditions: Biliary Tract Cancer, Biliary Tract Neoplasms
Interventions: Nivolumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 3
States / cities: Duarte, California • Tampa, Florida • Atlanta, Georgia

Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Pancreatic Adenocarcinoma
Interventions: Prehabilitation; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 65 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Ovarian Neoplasms
Interventions: bevacizumab, erlotinib; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Advanced Cancer
Interventions: LY2090314, pemetrexed, Carboplatin, ranitidine; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 25 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Tampa, Florida • Nashville, Tennessee

Conditions: Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
Interventions: APL-101 Oral Capsules; Drug
Lead sponsor: Apollomics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 6
States / cities: Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 3 more

Conditions: Metastatic Cancer, Solid Tumor, Pancreatic Cancer, Urothelial Carcinoma, Head and Neck Cancer, Colorectal Cancer
Interventions: LYT-200, Tislelizumab, Gemcitabine/nab-paclitaxel; Drug
Lead sponsor: PureTech; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 12
States / cities: Los Angeles, California • Denver, Colorado • Sarasota, Florida + 6 more

Conditions: Advanced Tumors
Interventions: CPI-100, Capecitabine; Drug
Lead sponsor: Coordination Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Grand Rapids, Michigan • Cleveland, Ohio • San Antonio, Texas

Conditions: Leukemia, Lymphocytic, Acute, Leukemia, Nonlymphocytic, Acute, Leukemia, Myeloid, Chronic, Myelodysplastic Syndromes
Interventions: Vosaroxin; Drug
Lead sponsor: Sunesis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 5
States / cities: Tampa, Florida • Indianapolis, Indiana • Baltimore, Maryland + 2 more

Conditions: Recurrent Head and Neck Carcinoma, Locally Advanced Head and Neck Carcinoma
Interventions: Nivolumab, Porfimer Sodium, Interstitial Illumination Photodynamic Therapy, Quality of Life Assessment; Biological · Drug · Procedure + 1 more
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Locally Advanced/Metastatic HER2 Positive Solid Tumors
Interventions: BB-1701; Drug
Lead sponsor: Bliss Biopharmaceutical (Hangzhou) Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: San Francisco, California • Nashville, Tennessee • Fairfax, Virginia

Search by objective public record fields.

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma

A Study of SGN-CD228A in Advanced Solid Tumors

oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection

A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer

WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Oxaliplatin and Gemcitabine in Treating Patients With Advanced Cancer

A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma

Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies

Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers

Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT

Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer

A Study of LY2090314 in Patients With Advanced or Metastatic Cancer

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Study of CPI-100 in Patients With Advanced Tumors

Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies

Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer

A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors